Age: 54.0
Sex: F
Vaccine: COVID19
Symptoms: COVID-19, SARS-CoV-2 test
Clinical narrative: COVID-19; This spontaneous case was reported by a patient and describes the occurrence of COVID-19 (COVID-19) in a 56-year-old female patient who received mRNA-1273 (Moderna COVID-19 Vaccine) (batch nos. 048L21A, 041C, 031L20A and 026L20A) for COVID-19 vaccination.     Concurrent medical conditions included Psoriasis and Drug allergy (Unknown historical drug).   On 30-Dec-2020, the patient received first dose of mRNA-1273 (Moderna COVID-19 Vaccine) (unknown route) 1 dosage form. On 27-Jan-2021, received second dose of mRNA-1273 (Moderna COVID-19 Vaccine) (unknown route) dosage was changed to 1 dosage form. On 20-Sep-2021, received third dose of mRNA-1273 (Moderna COVID-19 Vaccine) (unknown route) dosage was changed to 1 dosage form. On 07-Apr-2022, received fourth dose of mRNA-1273 (Moderna COVID-19 Vaccine) (unknown route) dosage was changed to 1 dosage form. On an unknown date, the patient experienced COVID-19 (COVID-19). The patient was treated with NIRMATRELVIR, RITONAVIR (PAXLOVID) from 15-May-2022 to 19-May-2022 for COVID-19 treatment, at an unspecified dose and frequency; IBUPROFEN (ADVIL [IBUPROFEN]) from 15-May-2022 to 27-May-2022 at an unspecified dose and frequency; CETIRIZINE HYDROCHLORIDE (ZYRTEC [CETIRIZINE HYDROCHLORIDE]) from 24-May-2022 to 28-May-2022 at an unspecified dose and frequency and FLUTICASONE PROPIONATE (FLONASE [FLUTICASONE PROPIONATE]) at an unspecified dose and frequency. At the time of the report, COVID-19 (COVID-19) had not resolved.      DIAGNOSTIC RESULTS (normal ranges are provided in parenthesis if available): In May 2022, SARS-CoV-2 test: positive (Positive) still testing positive.         No concomitant medications information was reported.  After completing 5-day course of Paxlovid, patient's initial Covid symptoms were diminishing, and was feeling better. Four days after the treatment ended, however, patient started to feel worse and had new cold symptoms emerge including sneezing, coughing and increased fatigue. Five days later patient was still unable to work, take care of family, or care for medically compromised parents as patient was still testing positive.  Company comment: This spontaneous case was reported by a 56-year-old female patient, with no relevant medical history, who experienced non serious event of COVID-19  after receiving the fourth dose of mRNA-1273 vaccine. Exact onset date of the event was not provided. She was treated with Paxlovid; 4 days after treatment ended she started to feel worse and had newcold symptoms including sneezing, coughing and increased fatigue. Treatment also included ibuprofen, cetirizine hydrochloride and fluticasone propionate. Five days later she was still unable to work as SARS-CoV-2 test remained positive. The benefit-risk relationship of mRNA-1273 vaccine is not affected by this report. Sender's Comments: This spontaneous case was reported by a 56-year-old female patient, with no relevant medical history, who experienced non serious event of COVID-19 after receiving the fourth dose of mRNA-1273 vaccine. Exact onset date of the event was not provided. She was treated with Paxlovid; 4 days after treatment ended she started to feel worse and had newcold symptoms including sneezing, coughing and increased fatigue. Treatment also included ibuprofen, cetirizine hydrochloride and fluticasone propionate. Five days later she was still unable to work as SARS-CoV-2 test remained positive. The benefit-risk relationship of mRNA-1273 vaccine is not affected by this report.